Travere therapeutics announces orphan drug designation for sparsentan for the treatment of iga nephropathy

San diego, jan. 12, 2021 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that the u.s. food and drug administration (fda) has granted orphan drug designation to sparsentan for the treatment of iga nephropathy (igan), a rare kidney disorder and a leading cause of end-stage kidney disease (eskd). sparsentan is an investigational product candidate currently being evaluated for the treatment of igan, as well as focal segmental glomerulosclerosis (fsgs) in pivotal phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.
TVTX Ratings Summary
TVTX Quant Ranking